Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $15.9 million.
- Tango Therapeutics' Income from Continuing Operations rose 15445.88% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 1856.67%. This contributed to the annual value of -$130.3 million for FY2024, which is 2806.85% down from last year.
- As of Q3 2025, Tango Therapeutics' Income from Continuing Operations stood at $15.9 million, which was up 15445.88% from -$38.9 million recorded in Q2 2025.
- Tango Therapeutics' Income from Continuing Operations' 5-year high stood at $15.9 million during Q3 2025, with a 5-year trough of -$39.9 million in Q1 2025.
- For the 5-year period, Tango Therapeutics' Income from Continuing Operations averaged around -$24.3 million, with its median value being -$25.6 million (2024).
- As far as peak fluctuations go, Tango Therapeutics' Income from Continuing Operations plummeted by 95180677.97% in 2021, and later skyrocketed by 15445.88% in 2025.
- Quarter analysis of 5 years shows Tango Therapeutics' Income from Continuing Operations stood at -$22.1 million in 2021, then tumbled by 31.98% to -$29.1 million in 2022, then decreased by 5.65% to -$30.8 million in 2023, then decreased by 22.37% to -$37.6 million in 2024, then surged by 142.21% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$38.9 million for Q2 2025, and -$39.9 million during Q1 2025.